Ozempic and yogurt, a Zepbound shortage, and Costco gets in on weight loss drugs: Pharma news round up
Danone CEO Antoine de Saint-Affrique said surging demand for weight loss drugs could help the French yogurt maker. The Food and Drug Administration officially declared a shortage of Zepbound. And Costco is offering members prescriptions to weight loss drugs via its healthcare partner Sesame.
Check out those and more pharma news highlights.
The rise of Ozempic and Wegovy is good for the yogurt business, Danone CEO says
Unlike many other food executives, Danone CEO Antoine de Saint-Affrique is optimistic about what the the skyrocketing demand for GLP-1 weight loss drugs could mean for the French yogurt company.
Eli Lilly’s weight loss drug Zepbound is officially in a shortage
Eli Lilly’s popular weight loss drug Zepbound has joined its competitor, Novo Nordisk’s Wegovy, in officially being hit by a shortage. The Food and Drug Administration said Wednesday that two doses of the drug, along with some doses of the company’s diabetes medication Mounjaro, are in limited supply.
Costco is now prescribing Ozempic, Wegovy, and other weight loss drugs
Costco, the membership warehouse club known for its $1.50 hot dogs and $2,000 gold bars, is now offering its members prescriptions to Ozempic, Wegovy, and other weight loss drugs.
The U.K. is giving patients a treatment for the type of diabetes Ozempic can’t treat
The National Health Service in England will give out thousands of artificial pancreas systems to patients living with Type 1 diabetes, the government agency announced today.
The weight loss drug shortage is hitting Eli Lily’s Zepbound
Sales of a new class of weight loss drugs known as GLP-1s have transformed Eli Lilly and Novo Nordisk into the most valuable pharmaceutical companies in the world. Eli Lilly is now the world’s ninth largest company by market capitalization at $777 billion. But the high demand has also made it hard for some patients to have their prescriptions filled.
Ozempic costs just $5 to make, a study said. The backlash was swift
Novo Nordisk is facing two-pronged pressure from lawmakers and patient advocates to make its popular diabetes medication Ozempic more affordable. The calls come on the heels of a recent study that found it costs less than $5 to produce a month’s supply of Ozempic.